Indofarma (INAF) sells Remdesivir for Rp 1.3 million per vial

Reporter: Arfyana Citra Rahayu | Editor: Herlina Kartika Dewi

KONTAN.CO.ID – JAKARTA. PT Indofarma Tbk (INAF) add to the Covid-19 drug product portfolio, namely Remdesivir under the trade name Desrem ™. Remdesivir Inj 100 mg is an antiviral product produced by Mylan Laboratories Ltd under license from Gilead Sciences Inc, Foster City and the United States of America.

Indofarma’s Finance Director Herry Triyatno explained that Remdesivir was imported from Mylan, a USA company that produces it in India.

“We have marketed Remdesivir with the trade name Desrem ™. This week there are 20,000 vials available. As for the stock availability for this month, there are already +/- 400,000 vials,” he explained to Kontan.co.id, Monday (5/10) ).

Herry said the price of the drug Desrem ™ Remdesivir Inj 100 mg was more affordable, namely Rp 1.3 million / vial.

Also Read: Kimia Farma (KAEF) and Indofarma (INAF) produce and supply Covid-19 drugs

For information, the recommended dose of Remdesivir is for patients over 12 years of age and body weight over 40 kilograms, namely on the first day a single 200 mg dose of remdesivir is given by intravenous infusion.
Then for the second day onwards 100 mg is given once a day by intravenous infusion. The total duration of treatment must be at least 5 days and not more than 10 days.

President Director of Indofarma Arief Pramuhanto explained that Desrem ™ Remdesivir Inj 100mg has received Emergency Use Authorization (EUA) approval in Indonesia and has been approved by BPOM through the issuance of a Marketing Permit Number that has been issued on September 30, 2020.

“This drug is used in inpatients with Covid-19 in moderate-severe conditions,” he explained.

For information, Indofarma has also produced Oseltamivir 75gr Caps and already has this 40.06% Domestic Content Level (TKDN) certificate. Oseltamivir has been produced alone by INAF with a production capacity of 4.9 million capsules per month.

Although he has added to the Covid-19 drug portfolio, Herry has not been able to specify how much the contribution of Covid-19 drug sales will be to INAF’s revenue by the end of the year.

Also Read: Pursuing the Procurement of Covid-19 Medical Devices, Indofarma (INAF) Builds Rapid Test Equipment Factory

According to him, numbers are still dynamic. However, Herry said that the composition of the Pharma segment will be greater than the other segments.

In addition to medicines, Indofarma has also produced medical devices such as 3Play Medical Face Mask (Inamask), Hand Sanitizer (Clind), Rapid Test (Smart Diagnostic Covid19) to Mobile Diagnostic Real Time PCR, Isolation Transport Products to Virus Transport Media (VTM). .